Home » Conference Coverage » ASH 2022
HCPs May Not Fully Investigate Heavy Menstrual Bleeding Among Women and Girls

Patients and health care providers (HCPs) may have only limited awareness of the factors indicating that heavy menstrual bleeding (HMB) may be a symptom of an underlying bleeding disorder, according to research presented at the 2022 ASH Annual Meeting.
Previous research suggests that, although HMB is an issue for millions of women worldwide, HCPs do not perform key investigations in the case of a patient presenting with HMB symptoms. These findings are especially salient given that approximately 20% of patients with HMB have an underlying bleeding disorder. For this study, researchers aimed to evaluate HCP and patient awareness of HMB and bleeding disorders among both women and girls.
The study consisted of 2 phases: the first was interview based; the second involved workshops that included both clinicians (including general practitioners and specialists in obstetrics and gynecology; GPs and OB/GYN, respectively) and patient advocates. The authors defined HMB as periods of longer than 8 days, as well as the presence of clots or use of 1 or more sanitary products in a given 2-hour period.
Continue Reading
Results showed that 76% of women believed they would be able to recognize HMB symptoms well, although 23% noted they would not consult a clinician in the case of a period lasting 8 or more days. Furthermore, 22% of consulted GPs felt they lacked confidence in the diagnosis of HMB.
Only 34% of GPs and 56% of OB/GYNs reported that they would “strongly associate” HMB after menarche with an underlying bleeding disorder, and less than 10% of GPs and OB/GYNs investigate further when a patient presents with a high bleeding score.
Among HCPs, notably, the differences in survey responses were not significant based HCP gender.
Disclosure: Some study authors declared affiliations with biotech, pharmaceutical, or device companies. Please see the original reference for a full list of authors’ disclosures.
Reference
Abdul-Kadir R, Tarawah A, Shridhar N, Kulkarni R. Driving change: improving diagnosis and awareness of heavy menstrual bleeding and bleeding disorders in women and girls among healthcare providers. Presented at ASH 2022. December 10-13, 2022. Abstract 1149.
Patients and health care providers (HCPs) may have only limited awareness of the factors indicating that heavy menstrual bleeding (HMB) may be a symptom of an underlying bleeding disorder, according to research presented at the 2022 ASH Annual Meeting.
Previous research suggests that, although HMB is an issue for millions of women worldwide, HCPs do not perform key investigations in the case of a patient presenting with HMB symptoms. These findings are especially salient given that approximately 20% of patients with HMB have an underlying bleeding disorder. For this study, researchers aimed to evaluate HCP and patient awareness of HMB and bleeding disorders among both women and girls.
The study consisted of 2 phases: the first was interview based; the second involved workshops that included both clinicians (including general practitioners and specialists in obstetrics and gynecology; GPs and OB/GYN, respectively) and patient advocates. The authors defined HMB as periods of longer than 8 days, as well as the presence of clots or use of 1 or more sanitary products in a given 2-hour period.
Results showed that 76% of women believed they would be able to recognize HMB symptoms well, although 23% noted they would not consult a clinician in the case of a period lasting 8 or more days. Furthermore, 22% of consulted GPs felt they lacked confidence in the diagnosis of HMB.
Only 34% of GPs and 56% of OB/GYNs reported that they would “strongly associate” HMB after menarche with an underlying bleeding disorder, and less than 10% of GPs and OB/GYNs investigate further when a patient presents with a high bleeding score.
Among HCPs, notably, the differences in survey responses were not significant based HCP gender.
Disclosure: Some study authors declared affiliations with biotech, pharmaceutical, or device companies. Please see the original reference for a full list of authors’ disclosures.
Reference
Abdul-Kadir R, Tarawah A, Shridhar N, Kulkarni R. Driving change: improving diagnosis and awareness of heavy menstrual bleeding and bleeding disorders in women and girls among healthcare providers. Presented at ASH 2022. December 10-13, 2022. Abstract 1149.
Continuing Medical Education (CME/CE) Courses
Show More
Please login or register first to view this content.
Copyright © 2022 Haymarket Media, Inc. All Rights Reserved
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.
Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions.
Enjoying our content?
Thanks for visiting Hematology Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Hematology Advisor. Register for free and gain unlimited access to:
– Clinical Updates, with personalized daily picks for you
– Evidence-Based Guidance
– Conference Coverage
– Full-Length Features
– Drug Monographs
– And More
{{login-button}} {{register-button}}
Please login or register first to view this content.